Vincerx Pharma, Inc. (VINC)
OTCMKTS · Delayed Price · Currency is USD
0.0456
-0.0019 (-3.98%)
At close: Jul 17, 2025

Vincerx Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
12.9713.5813.6418.8922.583.6
Upgrade
Research & Development
11.9515.4928.9749.8440.082.12
Upgrade
Operating Expenses
24.9229.0642.6168.7262.665.71
Upgrade
Operating Income
-24.92-29.06-42.61-68.72-62.66-5.71
Upgrade
Interest & Investment Income
0.370.471.250.66--
Upgrade
Other Non Operating Income (Expenses)
4.30.921.27.5423.35-5.91
Upgrade
EBT Excluding Unusual Items
-20.25-27.67-40.16-60.52-39.31-11.62
Upgrade
Merger & Restructuring Charges
-2.4-2.4--2.47--
Upgrade
Pretax Income
-22.65-30.07-40.16-62.98-39.31-16.62
Upgrade
Net Income
-22.65-30.07-40.16-62.98-39.31-16.62
Upgrade
Net Income to Common
-22.65-30.07-40.16-62.98-39.31-16.62
Upgrade
Shares Outstanding (Basic)
321110
Upgrade
Shares Outstanding (Diluted)
321110
Upgrade
Shares Change (YoY)
135.37%78.22%1.29%22.43%227.04%17.65%
Upgrade
EPS (Basic)
-8.98-15.85-37.71-59.90-45.77-63.29
Upgrade
EPS (Diluted)
-8.98-15.85-37.71-59.90-45.77-63.29
Upgrade
Free Cash Flow
-22.84-26.13-40.45-59.6-33.66-2.28
Upgrade
Free Cash Flow Per Share
-9.06-13.77-37.98-56.69-39.19-8.68
Upgrade
EBITDA
-24.87-29.01-42.56-68.67-62.63-
Upgrade
D&A For EBITDA
0.050.050.050.050.03-
Upgrade
EBIT
-24.92-29.06-42.61-68.72-62.66-5.71
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.